Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04HYP
|
|||
Former ID |
DNC000133
|
|||
Drug Name |
ABT-594
|
|||
Synonyms |
Tebanicline; ABT-594; 198283-73-7; Tebanicline [INN]; UNII-9KX8NKV538; CHEMBL430497; ABT594; 9KX8NKV538; (R)-5-(2-Azetidnylmethoxy)-2-chloropyridine; 5-((2R)-Azetidinylmethoxy)-2-chloropyridine; Pyridine, 5-(2-azetidnylmethoxy)-2-chloro-, (R)-; (R)-5-(azetidin-2-ylmethoxy)-2-chloropyridine; 5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine; Ebanicline; TEBENICILINE; AC1MIP4S; Tebanicline(ABT-594); SCHEMBL120178; GTPL3989; DTXSID90173555; MolPort-044-727-781; MKTAGSRKQIGEBH-SSDOTTSWSA-N; EX-A2483; BCP19181; ZINC3959783; BDBM50062641
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Structure |
Download2D MOL |
|||
Formula |
C9H11ClN2O
|
|||
Canonical SMILES |
C1CNC1COC2=CN=C(C=C2)Cl
|
|||
InChI |
1S/C9H11ClN2O/c10-9-2-1-8(5-12-9)13-6-7-3-4-11-7/h1-2,5,7,11H,3-4,6H2/t7-/m1/s1
|
|||
InChIKey |
MKTAGSRKQIGEBH-SSDOTTSWSA-N
|
|||
CAS Number |
CAS 198283-73-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neuronal acetylcholine receptor alpha-4 (CHRNA4) | Target Info | Agonist | [1] |
Neuronal acetylcholine receptor beta-2 (CHRNB2) | Target Info | Agonist | [1] | |
Nicotinic acetylcholine receptor (nAChR) | Target Info | Agonist | [1], [2] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Cholinergic synapse | ||||
Nicotine addiction | ||||
Panther Pathway | Nicotinic acetylcholine receptor signaling pathway | |||
Nicotine pharmacodynamics pathway | ||||
Reactome | Highly sodium permeable acetylcholine nicotinic receptors | |||
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
Highly calcium permeable nicotinic acetylcholine receptors | ||||
WikiPathways | SIDS Susceptibility Pathways | |||
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
Nicotine Activity on Dopaminergic Neurons |
References | Top | |||
---|---|---|---|---|
REF 1 | The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13. | |||
REF 2 | ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998 May;285(2):787-94. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.